Compare AstraZeneca plc (AZN) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

SHY, a US Treasury bond ETF, trades at $81.79, down 0.11% with a bearish technical signal from moving averages. The fund maintains consistent dividend distributions of $0.24 per share scheduled through mid-2026. Current market sentiment reflects significant investor interest in cash and Treasury ETFs as bond yields rise, with nearly $100 billion flowing into cash ETFs according to recent reports.

The outlook for SHY remains tied to Federal Reserve policy decisions amid inflation concerns. While the ETF provides stable income through Treasury exposure, rising rate expectations could pressure short-term bond prices. Investors seeking yield may find competition from higher-yielding alternatives as Treasury yields approach 4% levels.